Shukra Medtech Ltd Business Overview - SOIC x StockScans Report

as of Jul 2026

Shukra Pharmaceuticals is a pharmaceutical manufacturer that spent three decades building a WHO-GMP-certified formulations business from a single campus in Gujarat, then in 2025-26 made a sudden leap into medical technology distribution and healthcare services - a pivot executed not through internal R&D but by rapidly assembling a network of distribution authorisations, government service agreements, and two new subsidiaries. The recurring approach is visible in both eras: the company identifies a set of customers with specific procurement needs - whether global merchant exporters buying generic drugs or Indian defence hospitals buying surgical robots - and positions itself as the compliant, technically credible middleman who can develop, register, or represent the product and deliver it.

Business segments

Two engines at different stages - a mature pharmaceutical manufacturing and export business built on in-house formulation development, and a newly assembled medical technology distribution and services platform that went from zero to a full operating segment in under six months.

1. Pharmaceutical manufacturing and exports: the formulations engine the company was built on

A single-campus manufacturer that develops and ships generic drugs in multiple dosage forms to over 25 countries, earning its place through plant registrations and long-standing merchant-export relationships rather than proprietary molecules.

2. Shukra MedTech: a distribution-and-services platform assembled for government healthcare tenders

A newly created segment that does not manufacture anything itself but instead holds distribution rights, OEM authorisations, and a government PSU service agreement, all aimed at supplying medical devices and managing healthcare projects for India's defence and public-health institutions.

Group structure and partners

A promoter-led public company that operated without subsidiaries for most of its history, then incorporated two 85%-owned subsidiaries in late 2025 as vehicles for its MedTech ambitions, while its commercial partnerships span pharmaceutical merchant exporters and a rapidly assembled network of medical-device OEMs.